BioSpace News Archive

Syndax Pharmaceuticals (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy.

Actinium Pharmaceuticals, Inc. today announced that the Company will participate in the 2nd Annual Targeted Radiopharmaceuticals Summit in Boston, July 25 - 27, 2023.

Acurx Pharmaceuticals, Inc. announced today that the Company will discuss its second quarter 2023 financial results on Monday, August 14, 2023, at 8:00 am ET before the U.S. financial markets open.

LENSAR, Inc. announced that it has completed the installation of multiple ALLY Systems in five private equity-owned ophthalmology groups, including EyeSouth Partners’ network.

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that the company has entered into an agreement to acquire EryDel SpA.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce two orders for OxC-beta™.

Orthogon Therapeutics LLC today announced a dual victory. Orthogon’s lead molecule has successfully completed acute toxicity studies, marking a pivotal technical milestone that has unlocked an additional $3M from its dedicated syndicate of healthcare investors.

Crescendo Biologics Ltd today announces that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort.

Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: ADCT), today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA.

Labcorp announced today it now offers menopause testing through its Labcorp OnDemand digital health platform.